CN1048157C - Compounded injection of ribonucleic acid and heparin - Google Patents
Compounded injection of ribonucleic acid and heparin Download PDFInfo
- Publication number
- CN1048157C CN1048157C CN95111100A CN95111100A CN1048157C CN 1048157 C CN1048157 C CN 1048157C CN 95111100 A CN95111100 A CN 95111100A CN 95111100 A CN95111100 A CN 95111100A CN 1048157 C CN1048157 C CN 1048157C
- Authority
- CN
- China
- Prior art keywords
- heparin
- ribonucleic acid
- injection
- present
- compound injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Abstract
The present invention relates to biochemical compound injection for treating chronic viral hepatitis and liver cirrhosis. Ribonucleic acid and heparin are mixed into a whole. The compounding ratio of each branch of biochemical compound injection is 6 to 12 milligrams of ribonucleic acid, 2000 to 6000 international units of heparin and 3 to 5 milliliters of water for injection. The biochemical compound injection for treating chronic viral hepatitis and liver cirrhosis of the present invention can remarkably improve curative effect.
Description
The present invention relates to a kind of compound injection, the hardened biochemical compound injection of particularly a kind of treatment chronic viral hepatitis regulating liver-QI.
Clearly put down in writing by Pharmacopoeia of People's Republic of China, ribonucleic acid is the biochemical injectable drug of two kinds of different purposes with heparin.The former synthesizes protection hepatocyte, the synthetic regulating liver-QI cytothesis of promotion DNA and albumin obvious curative effects, also has the effect of obvious anti-hepatocyte fibrosis, to improving the hardened Proteometabolism of chronic hepatitis regulating liver-QI certain curative effect is arranged also.The latter is used for clinical existing more than 50 year history, mainly as the biochemical drug of anticoagulation, has anticoagulant, improves liver microcirculation, strengthens effect such as liver blood perfusion.But ribonucleic acid must keep its therapeutical effect of macromole integrity competence exertion of its breath of taking a message and obtain curative effect, owing to extensively have ribonucleic acid hydrolase in the human body, to be used for the treatment of and be injected into the hydrolysis at short notice of the intravital ribonucleic acid of people, so it is shorter to be injected into the intravital ribonucleic acid half-life, so the ribonucleic acid curative effect is restricted, and will has heavy dose of ribonucleic acid just can obtain certain curative effect.And use heparin separately, and then its consumption degree of accuracy is required very highly, amount has been lacked and has not just been reached therapeutic effect, has measured big will suppress the human body blood coagulation system, and has caused the hemorrhage of each organ of patient, even be in peril of one's life.Up to the present, the research report that does not also have the accurate consumption of ribonucleic acid and heparin compatibility.
Purpose of the present invention is exactly in order to address the above problem, and proposes a kind of ribonucleic acid and heparin compound injection, its energy competitive inhibition ribonucleic acid hydrolase, raising evident in efficacy.
Technical solution of the present invention:
A kind of ribonucleic acid and heparin compound injection is characterized in that it is mixed into one with ribonucleic acid and heparin, and its every proportioning is:
Ribonucleic acid 6-12 milligram
Heparin 2000-6000 iu
Water for injection 3-5 milliliter
Compound injection of the present invention is at treatment chronic hepatitis and liver cirrhosis, no matter improve each side such as patients clinical symptom, sign and liver function and antiviral curative effect, all significantly be better than single curative effect, and the remarkable statistical difference opposite sex (p＜0.05-0.01) is arranged with the ribonucleic acid treatment.Because the heparin of the present invention's mixing adding can suppress ribonucleic acid hydrolase, thus the ribonucleic acid that guarantees to enter human body take a message the macromolecular integrity of breath and play a role, heparin itself also has the liver of enhancing blood circulation etc. to coordinate effect in addition, so raising evident in efficacy.Compound recipe proportioning of the present invention can guarantee the accurate scope of consumption of heparin again simultaneously, the hemorrhage side effect of Denging can not occur.
Embodiment:
Get 10 milligrams of ribonucleic acid substrate, add heparin sodium (or calciparine) water preparation of 3000 ius then, and add 4 milliliters of waters for injection and make them fully mix filling bottle encapsulation promptly to make a water injection of the present invention.If with making powder for injection of the present invention after the freeze-drier processing.
Among the present invention; the optimum amount of heparin is 3000 ius in every injection; it can either protect the macromolecular integrity of ribonucleic acid in the 6-12 nanogram range; prolong its half-life; the performance optimum curative effect; simultaneously be again the safety using amount of heparin, can not cause side effect such as each organ hemorrhage of patient.If the heparin consumption is lower than 3000 ius, curative effect reduces, if surpass 6000 ius, hemorrhage danger is increased.
Claims (2)
1, a kind of ribonucleic acid and heparin compound injection is characterized in that it is mixed into one with ribonucleic acid and heparin, and its every proportioning is:
Ribonucleic acid 6-12 milligram
Heparin 2000-6000 iu
Water for injection 3--5 milliliter
2, by described ribonucleic acid of claim 1 and heparin compound injection, the optimum amount that it is characterized in that heparin in every injection is 3000 ius.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95111100A CN1048157C (en) | 1995-06-30 | 1995-06-30 | Compounded injection of ribonucleic acid and heparin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95111100A CN1048157C (en) | 1995-06-30 | 1995-06-30 | Compounded injection of ribonucleic acid and heparin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1129101A CN1129101A (en) | 1996-08-21 |
| CN1048157C true CN1048157C (en) | 2000-01-12 |
Family
ID=5078416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95111100A Expired - Lifetime CN1048157C (en) | 1995-06-30 | 1995-06-30 | Compounded injection of ribonucleic acid and heparin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1048157C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8685421B2 (en) | 2006-07-07 | 2014-04-01 | Surmodics, Inc. | Beaded wound spacer device |
| US9155671B2 (en) | 2012-10-16 | 2015-10-13 | Surmodics, Inc. | Wound packing device and methods |
-
1995
- 1995-06-30 CN CN95111100A patent/CN1048157C/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| 《中华内科杂志》22卷1期 1983.1.1 钟佛锦，核糖核酸和肝素治疗慢性活动性肝炎与肝硬化临床观察 * |
| 《江苏医药》16卷12期 1990.6.1 钟佛锦，肝素配伍治疗慢性活动性病毒性肝炎疗效观察 * |
| 《江苏医药》16卷12期 1990.6.1 钟佛锦，肝素配伍治疗慢性活动性病毒性肝炎疗效观察;《中华内科杂志》22卷1期 1983.1.1 钟佛锦，核糖核酸和肝素治疗慢性活动性肝炎与肝硬化临床观察 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8685421B2 (en) | 2006-07-07 | 2014-04-01 | Surmodics, Inc. | Beaded wound spacer device |
| US8697106B2 (en) | 2006-07-07 | 2014-04-15 | Surmodics, Inc. | Coating composition |
| US9155671B2 (en) | 2012-10-16 | 2015-10-13 | Surmodics, Inc. | Wound packing device and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1129101A (en) | 1996-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU643753B2 (en) | Thrombin composition for oral administration | |
| RU97107611A (en) | DRUGS OF ALPHA-INTERFERON IN THE FORM OF STABLE AQUEOUS SOLUTION | |
| DK0417725T3 (en) | Bile acid derivatives, processes for their preparation and use as pharmaceuticals. | |
| CN101287457A (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| CN1371287A (en) | Preserved pharmaceutical formulations | |
| EP0162764A1 (en) | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | |
| KR100397034B1 (en) | Non-inorganic salt solution for nasal administration | |
| EP0206947A2 (en) | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | |
| BR0014946A (en) | Use of dipyridamole or mopidamol in the manufacture of a drug for the treatment and prevention of fibrin-dependent microcirculatory disorders | |
| JPH10500678A (en) | Use of magnesium-based products for the treatment or prevention of neoplastic and autoimmune diseases | |
| CN1048157C (en) | Compounded injection of ribonucleic acid and heparin | |
| CN1326356A (en) | Method of treating viral hemorrhagic fever | |
| KR100255095B1 (en) | Therapeutic agent for threatened abortion | |
| WO2004028457A3 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY | |
| CA1336491C (en) | Antiviral pharmaceutical composition | |
| CN1058154C (en) | Medicine for treatment of pile | |
| CN1385154A (en) | Slow-releasing injection type demehylcantharidin for antitumor | |
| CN1488399A (en) | Medicinal use of agkistrodon acutus thrombase for treating hemorrhagic disease | |
| OA11180A (en) | Topical preparation for introducing peptidaceous pharmacons in living organisms | |
| JPS59181223A (en) | Stabilization of interferon | |
| JPH0717500B2 (en) | Stable injectable pharmaceutical formulation of 1,4-dihydroxy-5,8-bis [2- (2-hydroxyethylamino) -ethylamino] anthraquinone dihydrochloride | |
| CN107890460B (en) | Disodium adenosine triphosphate composition powder injection | |
| Marinella | Trimethoprim-sulfamethoxazole associated with hyperkalemia. | |
| CN1093765C (en) | Chaiqi injection for treating viral hepatitis | |
| CN1739536A (en) | A kind of compound formulation that contains monopotassium glycyrrhizunate and preparation method thereof and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20150630 Granted publication date: 20000112 |
|
| EXPY | Termination of patent right or utility model |